Dr Sean Leng and the Johns Hopkins-SunInflam team received a $1 million XPRIZE Healthspan Milestone 2 award for work targeting inflammaging — the chronic, low-grade inflammation that accumulates with age and tracks with frailty, cognitive decline and poor infection response. The award carries guaranteed access to clinical testing infrastructure built for aging trials, moving the approach from mechanism to human measurement. Restoring immune competence in later life addresses one of the most consistent drivers of functional decline.
Key Points
- Johns Hopkins-SunInflam team awarded $1M XPRIZE Healthspan Milestone 2
- Approach targets inflammaging driving frailty and weakened infection response
- Prize required early human evidence on muscle, brain or immune function
Longevity Analysis
Immune decline is rarely experienced as an immune problem — it surfaces as slower recovery, diminished vaccine response, muscle loss and cognitive dulling, which is precisely why chronic low-grade inflammation is so often misattributed to unrelated causes. Treating inflammation as a measurable, modifiable signal rather than an inevitability reframes late-life frailty as something that can be tracked and intervened upon. The prize structure itself enforces what the field has lacked: human data, standardized functional endpoints, and sustained testing over years rather than mechanistic promise.
Original published by Longevity.Technology, by Kyle Umipig.